# A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

Source: https://onco.cc/trials/nct07099898/  
OnCo record `nct07099898` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Topotecan in small-cell lung cancer, run by GlaxoSmithKline, now recruiting.

## Summary

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) is a phase 3 interventional study registered as NCT07099898 by GlaxoSmithKline, with 420 participants planned, started 2025-08-11 and due to reach its primary completion in 2027-11-05. Interventions recorded: Ris-Rez and Topotecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07099898
- Phase: 3
- Setting: Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)
- Sponsor: GlaxoSmithKline
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT07099898: https://clinicaltrials.gov/study/NCT07099898

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Topotecan](https://onco.cc/drugs/topotecan/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07099898.json